Advanced search
Publication Cover
Animal Cells and Systems Volume 28, 2024 - Issue 1
Submit an article Journal homepage
513
Views
0
CrossRef citations to date
0
Altmetric
Research Article

MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer

Suyeon Kima Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Ki Wook Leea Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Yongjin Yoob Department of Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA, USAView further author information
,
Sang Hee Parka Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Ji Won Leea Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Suhyun Jeonc Department of Biosciences, Mokpo National University, Muan, Republic of KoreaView further author information
,
Shaginyan Illiaa Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Pooja Joshid Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USAView further author information
,
Hyun Woo Parka Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Han-En Loa Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Jimin Seoa Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Yeonwoo Kima Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Min Changa Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
,
Tae Jin Leee Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USAView further author information
,
Jong Bae Seoc Department of Biosciences, Mokpo National University, Muan, Republic of KoreaView further author information
,
Sung-Hak Kimf Department of Animal Science, Chonnam National University, Gwangju, Republic of KoreaView further author information
,
Carlo M. Croced Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USAView further author information
,
Inki Kimg ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of KoreaView further author information
,
Sung-Suk Suhc Department of Biosciences, Mokpo National University, Muan, Republic of KoreaCorrespondence[email protected] [email protected]
View further author information
&
Young-Jun Jeona Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of KoreaView further author information
 show all
Pages 184-197 | Received 15 Jan 2024, Accepted 11 Apr 2024, Published online: 30 Apr 2024

References

  • Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation. 104(2):155–162. doi:10.1172/JCI6926.
  • Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Nature. 483(7391):603–607. eng. doi:10.1038/nature11003.
  • Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Science. 286(5443):1358–1362. eng. doi:10.1126/science.286.5443.1358.
  • Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Nature Reviews Cancer. 6(11):857–866. eng. doi:10.1038/nrc1997.
  • Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway [Research Support, Non-U.S. Gov't]. Immunity. 7(6):821–830. eng. doi:10.1016/S1074-7613(00)80400-8.
  • Chen X, Kandasamy K, Srivastava RK. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling [Research Support, Non-U.S. Gov't]. Cancer Research. 63(5):1059–1066. eng.
  • Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B [Research Support, N.I.H., Extramural]. PNAS. 104(40):15805–15810. eng. doi:10.1073/pnas.0707628104.
  • Flamini V, Jiang WG, Cui Y. 2017. Therapeutic role of MiR-140-5p for the treatment of non-small cell lung cancer. Anticancer Research. 37(8):4319–4327. eng.
  • Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, et al. 2013. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial. Cancer. 119(24):4290–4298. doi:10.1002/cncr.28353.
  • Genc S, Yagci T, Vageli DP, Dundar R, Doukas PG, Doukas SG, Tolia M, Chatzakis N, Tsatsakis A, Taghizadehghalehjoughi A. 2023. Exosomal microRNA-223, microRNA-146, and microRNA-21 profiles and biochemical changes in laryngeal cancer. ACS Pharmacology & Translational Science. 6(5):820–828. doi:10.1021/acsptsci.3c00038.
  • Grunert M, Gottschalk K, Kapahnke J, Gundisch S, Kieser A, Jeremias I. 2012. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-kappaB by TRAIL [Research Support, Non-U.S. Gov't]. Cell Death & Disease. 3:e414. eng. doi:10.1038/cddis.2012.154.
  • Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, Kim HJ, Wongchenko M, Yan Y, Haley B, et al. 2017. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer cell. 32(2):221–237. e213. eng. doi:10.1016/j.ccell.2017.07.002.
  • Hall MA, Cleveland JL. 2007. Clearing the TRAIL for cancer therapy [comment review]. Cancer cell. 12(1):4–6. eng. doi:10.1016/j.ccr.2007.06.011.
  • Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, et al. 2016. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. Nature Medicine. 22(3):262–269. eng. doi:10.1038/nm.4040.
  • Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, et al. 2010. A first-in-human study of conatumumab in adult patients with advanced solid tumors [Clinical Trial, Phase I Research Support, Non-U.S. Gov't]. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(23):5883–5891. eng. doi:10.1158/1078-0432.CCR-10-0631.
  • Hwang H, Chang HR, Baek D. 2023. Determinants of functional microRNA targeting. Molecules and Cells. 46(1):21–32. doi:10.14348/molcells.2023.2157.
  • Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, et al. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Nature Medicine. 7(8):954–960. eng. doi:10.1038/91000.
  • Im JY, Kim BK, Lee JY, Park SH, Ban HS, Jung KE, Won M. 2018. DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells [Research Support, Non-U.S. Gov't]. Oncogene. 37(9):1251–1262. eng. doi:10.1038/s41388-017-0025-y.
  • Jeon YJ, Middleton J, Kim T, Lagana A, Piovan C, Secchiero P, Nuovo GJ, Cui R, Joshi P, Romano G, et al. 2015. A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. PNAS. 112(26):E3355–E3364. eng.
  • Joshi P, Jeon YJ, Lagana A, Middleton J, Secchiero P, Garofalo M, Croce CM. 2015. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. PNAS. 112(28):8650–8655. eng. doi:10.1073/pnas.1500886112.
  • Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research. 28(1):27–30. doi:10.1093/nar/28.1.27.
  • Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, et al. 2010. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biology & Therapy. 9(8):618–631. doi:10.4161/cbt.9.8.11264.
  • Ke J, Chen J, Liu X. 2022. Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinoma. Animal Cells and Systems. 26(2):52–61. doi:10.1080/19768354.2022.2056635.
  • Kim JY, Lee JY, Kim DG, Koo GB, Yu JW, Kim YS. 2011. TRADD is critical for resistance to TRAIL-induced cell death through NF-kappaB activation [Research Support, Non-U.S. Gov't]. FEBS letters. 585(14):2144–2150. eng. doi:10.1016/j.febslet.2011.05.034.
  • Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson Jr JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, et al. 2012. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology. 23(11):2834–2842. doi:10.1093/annonc/mds142.
  • Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, et al. 2010. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(22):5529–5538. doi:10.1158/1078-0432.CCR-09-3403.
  • Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, Hollema H, den Dunnen WF. 2006. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. Journal of Neuro-Oncology. 78(2):161–171. doi:10.1007/s11060-005-9081-1.
  • Labovsky V, Martinez LM, Davies KM, de Lujan Calcagno M, Garcia-Rivello H, Wernicke A, Feldman L, Matas A, Giorello MB, Borzone FR, et al. 2017. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer. 17(1):280. doi:10.1186/s12885-017-3259-8.
  • Lara R, Seckl MJ, Pardo OE. 2013. The p90 RSK family members: common functions and isoform specificity [Review]. Cancer Research. 73(17):5301–5308. eng. doi:10.1158/0008-5472.CAN-12-4448.
  • Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. 2014. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer cell. 26(2):207–221. eng. doi:10.1016/j.ccr.2014.05.019.
  • Li B, Gu X, Zhang H, Xiong H. 2022. Comprehensive analysis of the prognostic value and immune implications of the TTK gene in lung adenocarcinoma: a meta-analysis and bioinformatics analysis. Animal Cells and Systems. 26(3):108–118. doi:10.1080/19768354.2022.2079718.
  • Li X, You M, Liu YJ, Ma L, Jin PP, Zhou R, Zhang ZX, Hua B, Ji XJ, Cheng XY, et al. 2017. Reversal of the apoptotic resistance of non-small-cell lung carcinoma towards TRAIL by natural product Toosendanin [Research Support, Non-U.S. Gov't]. Scientific Reports. 7:42748. eng. doi:10.1038/srep42748.
  • Lu M, Marsters S, Ye X, Luis E, Gonzalez L, Ashkenazi A. 2014. E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Molecular Cell. 54(6):987–998. eng. doi:10.1016/j.molcel.2014.04.029.
  • Macher-Goeppinger S, Aulmann S, Tagscherer KE, Wagener N, Haferkamp A, Penzel R, Brauckhoff A, Hohenfellner M, Sykora J, Walczak H, et al. 2009. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(2):650–659. doi:10.1158/1078-0432.CCR-08-0284.
  • McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM, Bartel DP. 2019. The biochemical basis of microRNA targeting efficacy. Science. 366(6472):p. eaav174110.1126/science.aav1741.
  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. 2008. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [Review]. Mayo Clinic Proceedings. 83(5):584–594. eng. doi:10.1016/S0025-6196(11)60735-0.
  • Oh YT, Liu X, Yue P, Kang S, Chen J, Taunton J, Khuri FR, Sun SY. 2010. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1 [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Journal of Biological Chemistry. 285(53):41310–41319. eng. doi:10.1074/jbc.M110.153775.
  • Omran OM, Ata HS. 2014. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer. The American Journal of Dermatopathology. 36(9):710–717. doi:10.1097/DAD.0b013e3182a3d31d.
  • Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. 1997. The receptor for the cytotoxic ligand TRAIL [Research Support, U.S. Gov't, P.H.S.]. Science. 276(5309):111–113. eng. doi:10.1126/science.276.5309.111.
  • Patel AR, Wedzicha JA, Hurst JR. 2011. Reduced lung-cancer mortality with CT screening [Letter Comment]. The New England Journal of Medicine. 365(21):2035. author reply 2037-2038. eng. doi:10.1056/NEJMc1110293.
  • Peng C, Cho YY, Zhu F, Xu YM, Wen W, Ma WY, Bode AM, Dong Z. 2010. RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. The FASEB journal : the journal of the Federation of American Societies for Experimental Biology. 24(9):3490–3499. eng. doi:10.1096/fj.09-151290.
  • Plaisier CL, Pan M, Baliga NS. 2012. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Genome Research. 22(11):2302–2314. eng. doi:10.1101/gr.133991.111.
  • Plantivaux A, Szegezdi E, Samali A, Egan L. 2009. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? [Review]. Annals of the New York Academy of Sciences. 1171:38–49. eng. doi:10.1111/j.1749-6632.2009.04725.x.
  • Poomakkoth N, Issa A, Abdulrahman N, Abdelaziz SG, Mraiche F. 2016. p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer. Journal of Translational Medicine. 14.(1410.1186/s12967-016-0768-1.
  • Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer [Research Support, Non-U.S. Gov't Review]. Oncogene. 26(22):3291–3310. eng. doi:10.1038/sj.onc.1210422.
  • Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. 2010. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cell. 141(4):583–594. eng. doi:10.1016/j.cell.2010.04.020.
  • Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, et al. 2007. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo [Research Support, Non-U.S. Gov't]. Biochemical Journal. 401(1):29–38. eng. doi:10.1042/BJ20061088.
  • Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB [Research Support, Non-U.S. Gov't]. Immunity. 7(6):831–836. eng. doi:10.1016/S1074-7613(00)80401-X.
  • Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. 2010. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cell. 141(1):69–80. eng. doi:10.1016/j.cell.2010.02.027.
  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277(5327):818–821. eng. doi:10.1126/science.277.5327.818.
  • Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, et al. 2004. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types [Research Support, U.S. Gov't, P.H.S.]. International Journal of Cancer. 109(5):786–792. eng. doi:10.1002/ijc.20041.
  • Siegel RL, Miller KD, Jemal A. 2018. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 68(1):7–30. eng. doi:10.3322/caac.21442.
  • Skelton W, Turba E, Sokol L. 2020. Durable complete response to AMG 655 (Conatumumab) and Vorinostat in a patient with relapsed classical Hodgkin Lymphoma: extraordinary response from a phase 1b clinical protocol. Clinical Lymphoma, Myeloma and Leukemia. 20(12):e944–e946. doi:10.1016/j.clml.2020.07.012.
  • Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, et al. 2016. Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cancer cell. 29(3):270–284. eng. doi:10.1016/j.ccell.2016.02.003.
  • Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 3:Article3. doi:10.2202/1544-6115.1027.
  • Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. 2003. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors [Research Support, Non-U.S. Gov't]. Clinical cancer research : an official journal of the American Association for Cancer Research. 9(9):3397–3405. eng.
  • Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P, Lehnert T. 2002. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clinical cancer research : an official journal of the American Association for Cancer Research. 8(12):3734–3740.
  • Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. 2012. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Molecular Cancer Therapeutics. 11(11):2541–2546. doi:10.1158/1535-7163.MCT-12-0358.
  • Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS. 102(43):15545–15550. doi:10.1073/pnas.0506580102.
  • Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. 2022. PANTHER: making genome-scale phylogenetics accessible to all. Protein Science. 31(1):8–22. doi:10.1002/pro.4218.
  • Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. PNAS. 103(7):2257–2261. eng. doi:10.1073/pnas.0510565103.
  • Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. 2007. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine. 13(9):1070–1077. eng. doi:10.1038/nm1627.
  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. 1998. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Science. 281(5383):1680–1683. eng. doi:10.1126/science.281.5383.1680.
  • Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H. 2024. Novel NF-kappaB inhibitor-conjugated Pt(IV) prodrug to enable cancer therapy through ROS/ER stress and mitochondrial dysfunction and overcome multidrug resistance. Journal of Medicinal Chemistry.
  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis [Research Support, Non-U.S. Gov't]. Immunity. 3(6):673–682. eng. doi:10.1016/1074-7613(95)90057-8.
  • Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. 2013. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells [Research Support, Non-U.S. Gov't]. Nucleic Acids Research. 41(Database issue):D955–D961. eng.
  • Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G. 2019. Serum microRNA signature is capable of early diagnosis for non-small cell lung cancer [Research Support, Non-U.S. Gov't]. International Journal of Biological Sciences. 15(8):1712–1722. eng. doi:10.7150/ijbs.33986.
  • Yuan Y, Shen Y, Xue L, Fan H. 2013. miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptor. PLoS One. 8(9):e73604. eng. doi:10.1371/journal.pone.0073604.
  • Zitzmann K, de Toni E, von Ruden J, Brand S, Goke B, Laubender RP, Auernhammer CJ. 2011. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells [Research Support, Non-U.S. Gov't]. Endocrine-Related Cancer. 18(2):277–285. eng. doi:10.1530/ERC-10-0108.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.